|
J 24.2:SP 3/3
|
DEA special agent : a career opportunity |
1 |
|
J 24.2:ST 8
|
Strategic plan FY 2003-FY 2008 |
1 |
|
J 24.2:SU 1/996
|
Controlled Substances Act as amended to February 15, 1996 : also includes chapter 53 of Title 31, United States Code, relating to monetary Instruments Transactions and Title 46, App. chapter 38: Maritime Drug Law Enforcement |
1 |
|
J 24.2:T 27/2/2006
|
Drugs & terrorism : teacher lesson plans |
1 |
|
J 24.2:Us 2
|
Time to focus on the user |
1 |
|
J 24.2:V 41
|
Vaping & marijuana concentrates : what is vaping? |
1 |
|
J 24.2:V 41/SPAN.
|
El cigarrillo electrónico y los concentrados de marihuana : ¿Qué es el "vapeo"? |
1 |
|
J 24.2:X 9
|
The growing threat of xylazine and its mixture with illicit drugs : DEA joint intelligence report |
1 |
|
J 24.29:
|
Drug trafficking in the United States |
1 |
|
J 24.30:
|
DEA update |
1 |
|
J 24.31:
|
Microgram bulletin |
1 |
|
J 24.31/2:
|
Microgram journal |
1 |
|
J 24.32:C 64
|
Colombian cocaine production expansion contributes to rise in supply in the United States |
1 |
|
J 24.32:F 36
|
Fentanyl remains the most significant synthetic opioid threat and poses the greatest threat to the opioid user market in the United States |
1 |
|
J 24.32:H 43
|
The 2015 heroin signature program report |
1 |
|
J 24.32:OP 3
|
The opioid threat in the Chicago Field Division |
1 |
|
J 24.34/2:
|
... Heroin Domestic Monitor Program |
1 |
|
J 24.34:003-21
|
Illicit opioid availability in Pennsylvania, 2020 |
1 |
|
J 24.34:004-21
|
Illicit stimulant availability in Pennsylvania, 2020 |
1 |
|
J 24.34:035-20
|
Counterfeit controlled prescription drug availability in Pennsylvania and Delaware |
1 |